X4-logo.png
X4 Pharmaceuticals to Participate in Three September Virtual Investor Conferences
September 03, 2020 08:00 ET | X4 Pharmaceuticals
CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from...
X4-logo.png
X4 Pharmaceuticals Announces Publication of Mavorixafor Phase 2 Clinical Data for Treatment of WHIM Syndrome in ‘Blood’ - the Official Journal of the American Society of Hematology
September 02, 2020 08:00 ET | X4 Pharmaceuticals
Manuscript further details positive clinical results and long-term tolerability of mavorixafor in ongoing Phase 2 study Company continues to advance mavorixafor in Phase 3 pivotal trial in WHIM using...
X4-logo.png
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2020 16:05 ET | X4 Pharmaceuticals
CAMBRIDGE, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq:  XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from...
X4-logo.png
X4 Pharmaceuticals to Present and Participate in the Canaccord Genuity’s 40th Annual Growth Conference
August 10, 2020 17:07 ET | X4 Pharmaceuticals
CAMBRIDGE, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from...
X4-logo.png
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 05, 2020 16:01 ET | X4 Pharmaceuticals
CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from...
X4-logo.png
X4 Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
July 30, 2020 08:00 ET | X4 Pharmaceuticals
Presentation of positive clinical data at EHA 2020 supporting the ongoing Phase 3 trial in WHIM syndrome Initial data expected later this year from Phase 1b clinical trial in Waldenström’s...
X4-logo.png
X4 Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on July 30, 2020
July 16, 2020 08:00 ET | X4 Pharmaceuticals
CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from...
X4-logo.png
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2020 08:00 ET | X4 Pharmaceuticals
CAMBRIDGE, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from...
X4-logo.png
X4 Pharmaceuticals Presents Positive Clinical Data from Phase 2 Study of Mavorixafor in WHIM Syndrome at EHA 2020
June 12, 2020 02:30 ET | X4 Pharmaceuticals
Sustained efficacy and safety trends observed for up to 28.6 months support ongoing pivotal Phase 3 trial dosing and endpoints, including selection of the measurement of time above threshold for...
X4-logo.png
X4 Pharmaceuticals Promotes Renato Skerlj, Ph.D., to Chief Scientific Officer
June 11, 2020 08:00 ET | X4 Pharmaceuticals
CAMBRIDGE, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from...